ArticleInternational journal of molecular sciences2026
Barbaloin Alleviates Lung Ischemia-Reperfusion Injury by Dual-Targeting IL-6 and PNP.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ischemia-reperfusion injury (IRI) remains a primary driver of primary graft dysfunction (PGD) following lung transplantation, yet effective therapeutic strategies are currently limited. Early IRI is driven by coordinated oxidative and inflammatory responses, highlighting the need for therapeutic strategies capable of targeting both processes simultaneously. Using integrated human multi-omics analysis, in silico target prediction, and experimental validation, we identified barbaloin as a dual-target lead compound acting on interleukin-6 (IL-6) and purine nucleoside phosphorylase (PNP). In vitro, barbaloin suppressed IL-6 and PNP expression, inhibited PNP activity, reduced reactive oxygen species (ROS) accumulation, and attenuated NF-κB/NLRP3 inflammatory signaling. Crucially, in vivo validation in a C57BL/6J mouse model demonstrated that barbaloin (15 mg/kg) attenuated pulmonary edema and histological injury, partially restored respiratory mechanics, and reduced IL-6 and PNP expression. Collectively, these findings support the IL-6/PNP axis as a critical mediator of early lung IRI and identify barbaloin as a promising dual-target therapeutic candidate for mitigating oxidative and inflammatory injury during lung transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.